MedPath

Copper oxodotreotide Cu-64

Generic Name
Copper oxodotreotide Cu-64
Drug Type
Small Molecule
Chemical Formula
C65H88CuN14O19S2
CAS Number
1426155-87-4
Unique Ingredient Identifier
N3858377KC

Overview

Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over Ga-labeled somatostatin analogs for positron emission tomography (PET). Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. Further studies should be performed to compare the two tracers. Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide. In a head-to-head trial, the former tracer detected twice as many lesions as the latter.

Background

Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over Ga-labeled somatostatin analogs for positron emission tomography (PET). Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. Further studies should be performed to compare the two tracers. Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide. In a head-to-head trial, the former tracer detected twice as many lesions as the latter.

Indication

Copper Cu 64 Dotatate is a radiopharmaceutical used with positron emission tomography(PET) to locate somatostatin receptor-positive neuroendocrine tumors.

Associated Conditions

  • Somatostatin Receptor Positive Neuroendocrine Tumours

FDA Approved Products

Detectnet
Manufacturer:CURIUM US LLC
Route:INTRAVENOUS
Strength:1.0 mCi in 1 mL
Approved: 2020/09/14
NDC:69945-064

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath